Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today the establishment of a new subsidiary, Sysmex Portugal, S.A. Going forward, Sysmex aims to increase its market presence by enhancing its sales and after-sales support networks in the country.
Since the 1979 creation of its public healthcare system, Portugal has maintained universal health insurance coverage, and its IVD market currently ranks 12th among European countries.1 Its per capita annual healthcare expenses are high, and demand for new testing in the life science field and elsewhere is expected to grow.
Sysmex first expanded to foreign markets in the early 1970s and, since establishing a UK subsidiary in 1991, has built direct sales and after-sales support networks outside of Japan. Now, 58 overseas affiliates (as of October 2020) deliver Sysmex products to over 190 countries and regions worldwide.
By building stable and long term relationships with customers, Sysmex hopes to develop insights into the needs of local customers to offer better solutions and to further increase its penetration into the IVD market, including hematology and urinalysis, while also expediting the market introduction of its products and services in the life science field.
Sysmex will remain committed to enhancing its global networks and offering a broad product line and attentive services and support, thus bringing greater trust and confidence to medical professionals.
Outline of Sysmex Portugal
Name: Sysmex Portugal, S.A. (TBD)
Location: Senhora da Hora, Portugal
Representative: Arndt Knestel
Capital: 139,600 EURO
Capital supplied by: Sysmex Europe GmbH (Sysmex Europe is a wholly owned subsidiary of Sysmex Corporation)
Employees: 19
Line of business: Sales and support services for in vitro diagnostic instruments and reagents
Note
1 The Worldwide Market for In Vitro Diagnostic Tests, 13th Edition (September 2020)
Information contained in the press release is current as of the date of the announcement but may be subject to change without prior notice.